Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
06 January 2023 - 8:03AM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that Paul R. Edick, Xeris’ Chairman
and CEO, will present an overview of the Company at the 41st Annual
J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at
12:00 pm Pacific Time. To access the presentation, please visit
“Events” on the investor relations page of the Company’s website at
www.xerispharma.com.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing innovative products across a range of therapies.
Xeris has three commercially available products; Gvoke®, a
ready-to-use liquid glucagon for the treatment of severe
hypoglycemia, Keveyis®, the first and only FDA-approved therapy for
primary periodic paralysis, and Recorlev® for the treatment of
endogenous Cushing’s syndrome. Xeris also has a robust pipeline of
development programs to extend the current marketed products into
important new indications and uses and bring new products forward
using its proprietary formulation technology platforms, XeriSol™
and XeriJect™, supporting long-term product development and
commercial success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn, or Instagram.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Xeris Biopharma Holdings, Inc. including
statements regarding the timing or likelihood of expansion into
additional markets, the likelihood of extending currently marketed
products into new indications and uses, the potential utility of
its formulation technology platforms and other statements
containing the words “will,” “would,” “continue,” “expect,” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on numerous
assumptions and assessments made in light of Xeris’ experience and
perception of historical trends, current conditions, business
strategies, operating environment, future developments,
geopolitical factors and other factors it believes appropriate. By
their nature, forward-looking statements involve known and unknown
risks and uncertainties because they relate to events and depend on
circumstances that will occur in the future. The factors described
in the context of such forward-looking statements in this
communication could cause Xeris’ actual results, performance or
achievements, industry results and developments to differ
materially from those expressed in or implied by such
forward-looking statements. Although it is believed that the
expectations reflected in such forward-looking statements are
reasonable, no assurance can be given that such expectations will
prove to have been correct and persons reading this communication
are therefore cautioned not to place undue reliance on these
forward-looking statements which speak only as of the date of this
communication. Additional information about potential impacts of
COVID-19, financial, operational, economic, competitive,
regulatory, governmental, technological, and other factors that may
affect Xeris is set forth in the "Risk Factors" section of the most
recently filed Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission, the contents of which are not
incorporated by reference into, nor do they form part of, this
communication. Subject to any obligations under applicable law,
Xeris does not undertake any obligation to update any
forward-looking statement whether as a result of new information,
future developments or otherwise, or to conform any forward-looking
statement to actual results, future events, or to changes in
expectations. All subsequent written and oral forward-looking
statements attributable to Xeris or any person acting on behalf of
any of Xeris are expressly qualified in their entirety by this
paragraph.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230105005632/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024